Skip to main content
Premium Trial:

Request an Annual Quote

Slight Revenue Uptick for Amersham Biosciences Discovery Unit

NEW YORK, April 30 - Amersham PLC had sales of ₤381 million ($608 million) for the first quarter of 2003, up 6 percent compared to the year-ago quarter, the company said today.

 

Amersham Biosciences, the Piscataway, NJ-based unit of London-based Amersham, has sales of ₤157 million ($251 million) for the quarter, including sales of ₤95 million ($152 million) for its restructured discovery systems division. The unit's sales grew by 2 percent, excluding discontinued product sales of ₤7 million ($11 million), with growth in proteomics and bioassays overcoming declines in genomics product lines, the company added.

 

In February, the company announced a restructuring in its discovery systems group, firing 400 workers, and reshuffling management in an effort to bring the unit to profitability by 2004.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.